Literature DB >> 25344144

Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy.

Adamu Issaka1, Nezih Onur Ermerak, Zeynep Bilgi, Volkan Hasan Kara, Cigdem Ataizi Celikel, Hasan Fevzi Batirel.   

Abstract

BACKGROUND: This study aimed to analyze the effect of preoperative chemoradiation on the adequacy of lymph node dissection.
METHODS: Patients with esophageal cancer treated with esophagectomy by the same surgeon between 2004 and 2011 were reviewed. Specimens were examined by the same pathologist. Patients were grouped into two depending on the type of treatment received.
RESULTS: Forty-seven patients with curative esophagectomy were included in the study. Twenty patients had preoperative chemoradiation followed by surgery and 27 had surgery alone. Open and hybrid esophagectomy approaches were used. The average number of lymph nodes dissected was 16 ± 10 (1-39). There was a significant decrease in the number of lymph nodes examined in patients with preoperative chemoradiotherapy in comparison to surgery alone (p = 0.001). Median length of stay was 12 days. R0 resection rate was 96%. The median survival was 36.3 months, with a 42% 5-year survival. Seven patients (25%) had complete pathologic response following chemoradiation. No significant difference was recorded in terms of disease recurrence (p = 0.3). While morbidity was higher in the preoperative therapy group with 30 day mortality of 10%, type of surgical approach does not seem to influence the number of lymph nodes dissected (p = 0.7).
CONCLUSIONS: Preoperative chemoradiation decreases the number of harvested lymph nodes following esophagectomy regardless of the surgical technique used. The optimum number of lymph nodes currently recommended to be dissected for accurate nodal staging and survival needs revision in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25344144     DOI: 10.1007/s00268-014-2847-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  Number of lymph nodes after neoadjuvant therapy for rectal cancer: How many are needed?

Authors:  Stefano Scabini; Valter Ferrando
Journal:  World J Gastrointest Surg       Date:  2012-02-27

2.  Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas?

Authors:  Gábor Cserni; Vincent Vinh-Hung; Tomasz Burzykowski
Journal:  J Surg Oncol       Date:  2002-10       Impact factor: 3.454

3.  The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system.

Authors:  Nabil Rizk; Ennapadam Venkatraman; Bernard Park; Raja Flores; Manjit S Bains; Valerie Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2006-12       Impact factor: 5.209

4.  Esophageal cancer recurrence patterns and implications for surveillance.

Authors:  Feiran Lou; Camelia S Sima; Prasad S Adusumilli; Manjit S Bains; Inderpal S Sarkaria; Valerie W Rusch; Nabil P Rizk
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

5.  A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.

Authors:  Kenneth A Kesler; Paul R Helft; Elizabeth A Werner; Neel P Jain; Jo Ann Brooks; John M DeWitt; Julia K Leblanc; Naomi S Fineberg; Lawrence H Einhorn; John W Brown
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

6.  Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Authors:  Carlo Castoro; Marco Scarpa; Matteo Cagol; Alberto Ruol; Francesco Cavallin; Rita Alfieri; Gianpietro Zanchettin; Massimo Rugge; Ermanno Ancona
Journal:  Ann Surg Oncol       Date:  2011-05-10       Impact factor: 5.344

7.  Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy.

Authors:  Brendon M Stiles; Abu Nasar; Farooq A Mirza; Paul C Lee; Subroto Paul; Jeffrey L Port; Nasser K Altorki
Journal:  Eur J Cardiothorac Surg       Date:  2012-04-04       Impact factor: 4.191

8.  Total number of resected lymph nodes predicts survival in esophageal cancer.

Authors:  Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

9.  Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean?

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Viviane Rawet; Diego D Pereira; Afonso H S Sousa; Desiderio Kiss; Ivan Cecconello
Journal:  Dis Colon Rectum       Date:  2008-03       Impact factor: 4.585

10.  Optimum lymphadenectomy for esophageal cancer.

Authors:  Nabil P Rizk; Hemant Ishwaran; Thomas W Rice; Long-Qi Chen; Paul H Schipper; Kenneth A Kesler; Simon Law; Toni E M R Lerut; Carolyn E Reed; Jarmo A Salo; Walter J Scott; Wayne L Hofstetter; Thomas J Watson; Mark S Allen; Valerie W Rusch; Eugene H Blackstone
Journal:  Ann Surg       Date:  2010-01       Impact factor: 12.969

View more
  1 in total

1.  Adequate Lymphadenectomy as a Quality Measure in Esophageal Cancer: Is there an Association with Treatment Approach?

Authors:  Cary Jo R Schlick; Rhami Khorfan; David D Odell; Ryan P Merkow; David J Bentrem
Journal:  Ann Surg Oncol       Date:  2020-06-09       Impact factor: 4.339

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.